Cancer
-
Boehringer Ingelheim partners with Zai Lab for dual-targeting lung cancer trial
The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).
-
Gilead pays USD45M to secure Kymera’s unique CDK2 molecular glue for cancer
Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.
-
Telix signs USD4.3 billion partnership with Regeneron to expand next-generation precision oncology
The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.
-
Roche broadens C4 Therapeutics partnership to develop DAC cancer pipeline
C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development
-
SEHA Tawam Hospital debuts histotripsy for non-invasive liver cancer treatment
Histotripsy uses precisely focused ultrasound energy to destroy tumours from outside the body, eliminating the need for surgery, radiotherapy, or chemotherapy.
-
Gilead acquires German biotech Tubulis for USD5B in major push into cancer drug development
The two companies began collaborating in 2024 through an option and license agreement valued at up to USD 465 million, which granted Gilead access to Tubulis’ proprietary ADC platforms.
-
NYU Abu Dhabi develops “Smart” theranostic molecules for cancer
The work centres on magnetic resonance imaging (MRI), a widely used diagnostic tool that allows doctors to visualise tumours inside the body.
-
Zimbabwe recalls Urografin imaging agent due to cancer-risk impurity
The recall covers all batches of Urografin 60% manufactured between October 2020 and March 2025.
-
ImmunityBio secures first Asian approval for Anktiva bladder cancer drug in Macau
The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.
-
Nigeria’s NAFDAC warns of counterfeit cancer drugs that threaten patient safety
The alert followed official communication from Roche Nigeria after the pharmaceutical company received multiple complaints from healthcare professionals nationwide.